Agrematch published Ouri Fischel's latest article examining how R&D teams navigate trade-offs between performance, cost, regulatory requirements, and market readiness.
Public source
Publisher name
Public post
R&D rarely gets the luxury of solving one requirement at a time. Performance needs to improve. Costs need to stay competitive. Ingredients become constrained. Regulatory…
Company
Agrematch
Function-First Chemistry for Enterprise R&D
- Industry
- Biotechnology Research
- Location
- Rehovot, IL
- Company size
- 11–50 employees
About Agrematch
Agrematch helps enterprise R&D teams solve complex chemistry challenges across discovery, development, formulation, and AI-enabled research. Through proprietary technology, predictive chemistry, and deep scientific expertise, Agrematch helps organizations discover new chemistry, improve active ingredient and ingredient mixes, optimize formulations, predict development risk, structure R&D data, and build custom AI workflows. Bring us a defined R&D goal, from a new active or functional ingredient to a better formulation, safer profile, improved mix, or AI-ready data challenge. We help identify the candidate options, formulation paths, predictive models, and workflows most likely to move it forward. Agrematch supports organizations across agriculture, food and nutrition, animal health and feed, specialty chemicals, materials, personal care, cosmetics, and broader bioactive applications.
See moreLatest activity
Latest activity from Agrematch
4 signals
Research & Knowledge
Agrematch's VP Business Development Ouri Fischel published an article exploring how chemistry-specific predictive AI helps R&D teams re-evaluate accumulated knowledge against new requirements.
Presence & Recognition
Agrematch participated in ACS Publications Fall 2026, bringing its perspective to the broader industry discussion from Chicago.
Presence & Recognition
Agrematch CEO Eyal Ben-Chanoch presented a look back at ACS Fall 2026 from the perspective of the chemistry community and chemistry-driven R&D opportunities.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
HitChem
HitChem discovered unique and diverse CRBN ligands through in-house research efforts, driving the expansion of the CRBN Molecular Glue Library.
Research & Knowledge
HighRes
HighRes published an article on closed-loop DMTA analyzing the translation gap between an AI-generated plan and an executable workflow in drug discovery.
Research & Knowledge
Drug Hunter
Drug Hunter published an article and accompanying poster covering eight small molecules from EFMC Medicinal Chemistry 2026 first time disclosure sessions, including AZD4248, NVP-ITU512, UCB6492, BI 706321, RG6182, zilurgisertib, and Clasornoflast.
Research & Knowledge
Intrepid Labs
Intrepid Labs Senior Director of Engineering Dr. Riley Hickman published an article for Lab Manager exploring how traditional measures of productivity in exploratory R&D do not fully capture the story.
Research & Knowledge
SpiroChem